A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2-p53 antagonist BI 907828 in patients (pts) with solid tumours

被引：2
|
作者：
Schoeffski, P. [1 ]
Yamamoto, N. [2 ]
Bauer, T. [3 ]
Patel, M. [4 ]
Gounder, M. M. [5 ]
Geng, J. [6 ]
Sailer, R. [7 ]
Jayadeva, G. [8 ]
Lorusso, P. [9 ]
机构：
[1] Univ Hosp Leuven, Leuven Canc Inst, Dept Gen Med Oncol, Leuven, Belgium
[2] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[3] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[4] Florida Canc Specialists Res Inst, Sarah Cannon Res Inst, Sarasota, FL USA
[5] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[6] Boehringer Ingelheim Pharmaceut Inc, Biostatist & Data Sci, Ridgefield, CT USA
[7] Boehringer Ingelheim Int GmbH, Dept Translat Med & Clin Pharmacol, Ingelheim, Germany
[8] Boehringer Ingelheim Int GmbH, Dept Med, Therapy Area Oncol, Ingelheim, Germany
[9] Yale Univ, Yale Canc Ctr, Sch Med, New Haven, CT USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.581
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
452O
引用
收藏
页码：S743 / S743
页数：1
相关论文
共 50 条
  • [31] Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.
    Zhang, Xing
    Wen, Xizhi
    Chen, Guojuan
    Zeng, Shan
    Men, Lichuang
    Wang, Hengbang
    He, Shulan
    Ma, Yuxiang
    Pan, QiuZhong
    Zhang, Yang
    Peng, Ruiqing
    Weng, Desheng
    Liu, Wenqin
    Zhang, Li
    Liang, Zhiyan
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    Diaz-Padilla, I.
    Siu, L. L.
    San Pedro-Salcedo, M.
    Razak, A. R. A.
    Colevas, A. D.
    Shepherd, F. A.
    Leighl, N. B.
    Neal, J. W.
    Thibault, A.
    Liu, L.
    Lisano, J.
    Gao, B.
    Lawson, E. B.
    Wakelee, H. A.
    BRITISH JOURNAL OF CANCER, 2012, 107 (04) : 604 - 611
  • [33] A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    I Diaz-Padilla
    L L Siu
    M San Pedro-Salcedo
    A R A Razak
    A D Colevas
    F A Shepherd
    N B Leighl
    J W Neal
    A Thibault
    L Liu
    J Lisano
    B Gao
    E B Lawson
    H A Wakelee
    British Journal of Cancer, 2012, 107 : 604 - 611
  • [34] Brightline-2: A phase IIa/IIb, open-label trial of the MDM2-p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma, or other selected solid tumours
    Macarulla, T.
    Harding, J.
    Morizane, C.
    Ohkawa, K.
    Ueno, M.
    Vogel, A.
    Lamarca, A.
    Yamamoto, N.
    Javle, M.
    Hu, J.
    Teufel, M.
    Marten, A.
    Goyal, L.
    Yoo, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S33 - S33
  • [35] Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results
    Voskoboynik, M.
    Mileshkin, L.
    Gan, H.
    Millward, M.
    Au-Yeung, G.
    Meniawy, T. M.
    Kichenadasse, G.
    Zhang, K.
    Zhang, M.
    Mu, S.
    Lickliter, J. D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
    Schoffski, Patrick
    Awada, Ahmad
    Dumez, Herlinde
    Gil, Thierry
    Bartholomeus, Sylvie
    Wolter, Pascal
    Taton, Martine
    Fritsch, Holger
    Glomb, Patricia
    Munzert, Gerd
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) : 179 - 186
  • [37] A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors
    Ferrarotto, R.
    Eckhardt, G.
    Patnaik, A.
    LoRusso, P.
    Faoro, L.
    Heymach, J. V.
    Kapoun, A. M.
    Xu, L.
    Munster, P.
    ANNALS OF ONCOLOGY, 2018, 29 (07) : 1561 - 1568
  • [38] A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors
    Tolcher, Anthony W.
    Bendell, Johanna C.
    Papadopoulos, Kyriakos P.
    Burris, Howard A.
    Patnaik, Amita
    Fairbrother, Wayne J.
    Wong, Harvey
    Budha, Nageshwar
    Darbonne, Walter C.
    Peale, Franklin
    Mamounas, Michael
    Royer-Joo, Stephanie
    Yu, Ron
    Portera, Chia C.
    Infante, Jeffrey R.
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4567 - 4573
  • [39] A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
    Shapiro, Geoffrey
    Supko, Jeffrey G.
    Cho, Daniel C.
    Hilton, John Frederick
    Hadfield, Matthew
    Pruitt-Thompson, Salida
    Bordoli-Trachsela, Eveline
    Zvereva, Nela
    Wolanski, Andrew
    Sato-DiLorenzo, Aya
    Gotthardt, Susan
    Fox, Edward A.
    Verselis, Sigitas Jonas
    Kumar, Ashok
    Holden, Sylvia A.
    Ram, Siya
    Chafai-Fadela, Karima
    Harding, Kimberly
    Menon, Krishna E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Phase I dose-escalation trial evaluating the safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors
    Awada, A.
    Gil, T.
    Whenham, N.
    Vanhamme, J.
    Mancini, I.
    Besse, T.
    Brendel, E.
    Loembe, B.
    Piccart, M.
    Hendlisz, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 39 - 39
12345